U.S. FDA approves Bristol Myers Squibb and 2seventy bio’s Abecma for multiple myeloma
The U.S. Food and Drug Administration (FDA) has approved Bristol Myers Squibb and 2seventy bio’s Abecma® (idecabtagene vicleucel; ide-cel) for the treatment of adult patients with relapsed or refractory multiple myeloma after two or more prior lines of …